ANDA 202253, held by Fresenius Kabi USA. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 202253 (Ondansetron Hydrochloride Preservative Free), held by Fresenius Kabi USA, was first approved by FDA on Jul 19, 2013, with 7 approved supplements and 0 published complete response letters.
Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. postoperative nausea and/or vomiting. 1.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron is approved for patients aged 6 months and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 19, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron Hydrochloride Preservative FreeEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Jul 8, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 12Manufacturing · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 16, 2015 | Supplement 5Labeling | Approved | None posted |
| Oct 22, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 22, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 9, 2015 | Supplement 1Manufacturing | Approved | None posted |
| Jul 19, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters